Myelodysplastic Syndrome Market Report 2026

The myelodysplastic syndrome market size has grown strongly in recent years. It will grow from $2.85 billion in 2025 to $3.12 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to limited treatment alternatives, rising prevalence of hematologic disorders, increased progression to aml, dependence on supportive care, challenges in early diagnosis.

The myelodysplastic syndrome market size is expected to see rapid growth in the next few years. It will grow to $4.65 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to growth in targeted therapies, expansion of precision medicine solutions, increased investment in oncology r&d, advancements in stem cell transplantation, rising adoption of oral hypomethylating drugs. Major trends in the forecast period include increasing adoption of hypomethylating agents, growing use of combination therapy approaches, rising focus on early detection and diagnostic accuracy, expansion of stem cell transplantation and regenerative options, increasing demand for supportive care and growth factor therapies.

The rising incidence of rare blood cancers is expected to propel the growth of the myelodysplastic syndrome (MDS) market going forward. Blood cancers are hematologic malignancies with relatively low incidence rates that originate in bone marrow cells, lymph nodes, and other components of the blood and immune system. Treatment for myelodysplastic syndrome focuses on managing the disorder by improving blood cell production, alleviating associated symptoms, and preventing progression to more aggressive blood cancers within the bone marrow. For instance, in September 2024, according to the Leukemia and Lymphoma Society, a US-based professional organization, one person in the United States is diagnosed with leukemia, lymphoma, or myeloma every three minutes. In 2024, an estimated 187,740 individuals were expected to be affected by these cancers, accounting for 9.4% of the projected 2,001,140 new cancer cases in the country. Therefore, the increasing incidence of blood cancers is driving the growth of the myelodysplastic syndrome (MDS) market.

Major companies operating in the myelodysplastic syndrome (MDS) market are concentrating on developing innovative approaches such as first-line erythroid maturation therapies to improve anemia management and reduce dependence on frequent red blood cell transfusions. First-line erythroid maturation therapies are targeted treatments designed to enhance late-stage red blood cell development, allowing earlier and more sustained correction of anemia in patients who have not previously received erythropoiesis-stimulating agents. For instance, in August 2023, Bristol Myers Squibb, a US-based pharmaceutical company, received FDA approval for Reblozyl (luspatercept-aamt) as a first-line treatment for anemia in ESA-naïve adults with low- to intermediate-risk myelodysplastic syndromes who may require regular red blood cell transfusions. In the Phase 3 COMMANDS trial, Reblozyl demonstrated superior effectiveness in achieving red blood cell transfusion independence and increasing hemoglobin levels compared with epoetin alfa, enabling earlier intervention across a broader patient population.

In October 2025, Launch One Acquisition Corp., a US-based special purpose acquisition company focused on healthcare and technology investments, entered into a business combination agreement with Minovia Therapeutics to form a Nasdaq-listed biotechnology company specializing in mitochondrial augmentation therapies. Through this transaction, Launch One aims to support Minovia’s capital needs, accelerate its clinical development programs, and facilitate its transition to a publicly traded company. Minovia Therapeutics is an Israel-based clinical-stage biotechnology firm developing mitochondrial cell therapies for rare diseases, including Pearson syndrome and myelodysplastic syndrome.

Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

North America was the largest region in the myelodysplastic syndrome market in 2025. The regions covered in the myelodysplastic syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myelodysplastic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical ingredients and oncology-related biologics have increased production and import costs in the myelodysplastic syndrome market, disrupting supply chains for both supportive and targeted treatments. Regions dependent on imported specialty drugs - such as parts of Asia-Pacific and Latin America - face higher pricing pressure and slower patient access. Despite these challenges, tariffs have encouraged domestic manufacturing capabilities and innovation in localized drug development, improving long-term supply stability.

The myelodysplastic syndrome market research report is one of a series of new reports that provides myelodysplastic syndrome market statistics, including myelodysplastic syndrome industry global market size, regional shares, competitors with a myelodysplastic syndrome market share, detailed myelodysplastic syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the myelodysplastic syndrome industry. This myelodysplastic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myelodysplastic syndrome (MDS) is a group of disorders marked by abnormal or ineffective development of bone marrow cells, resulting in poor blood cell production. Treatment for myelodysplastic syndrome focuses on improving blood cell counts, relieving symptoms, and slowing disease progression. In some cases, MDS can progress to acute myeloid leukemia (AML), a more aggressive blood cancer.

The main types of myelodysplastic syndrome include myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia, and myelodysplastic syndrome with ring sideroblasts, among others. Myelodysplastic syndrome with unilineage dysplasia represents a specific subtype within the MDS spectrum. Treatment options include drugs such as azacitidine, lenalidomide, decitabine, and deferasirox. Therapeutic approaches include supportive care, growth factor therapy, chemotherapy, stem cell transplantation, and others, with routes of administration including oral, injectable, and additional methods. These treatments are utilized by end users such as hospitals, homecare providers, specialty centers, and others.

The myelodysplastic syndrome (MDS) market consists of revenues earned by entities by providing experimental therapies, targeted therapies and blood transfusion. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelodysplastic syndrome (MDS) market also consists of sales of erythropoiesis-stimulating agents (ESAs) and immunomodulatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.